GSK Senior VP Rogerio Ribeiro On Trends In Emerging Markets: An Interview With PharmAsia News
This article was originally published in PharmAsia News
GSK operates in 172 emerging markets, which represented about 22% of the company’s revenues in 2013, and EM Head Rogerio Ribeiro is optimistic about further growth despite challenges in some markets.
You may also be interested in...
MUMBAI - Fifty years from now, the period between 2005 and 2020 may be seen as critical years of change when the world witnessed a fundamental shift in economic power from a model dominated for the last 250 years to an evolutionary one led by emerging markets rather than Western economies
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.